Oropharyngeal candidiasis in the era of antiretroviral therapy

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 109, Issue 4, 2010, Pages 488-495

  Thompson III, George R ^a,b   Patel, Payal K ^a   Kirkpatrick, William R ^a   Westbrook, Steven D ^b,c   Berg, Deborah ^a   Erlandsen, Josh ^a   Redding, Spencer W ^b,c   Patterson, Thomas F ^a,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT;

AIDS RELATED COMPLEX; ANTIFUNGAL RESISTANCE; CANDIDA; CLASSIFICATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY; OROPHARYNX; PHARYNX DISEASE; REVIEW; THRUSH;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; OROPHARYNX; PHARYNGEAL DISEASES;

EID: 77949489417     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2009.11.026     Document Type: Review

References (63)

1. Cameron D.W., Heath-Chiozzi M., Danner S., Cohen C., Kravcik S., Maurath C., et al., Advanced HIV Disease Ritonavir Study Group. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351 9102 (1998) 543-549
2. Hood S., Bonington A., Evans J., and Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 12 (1998) 447-448
3. Revankar S.G., Sanche S.E., Dib O.P., Caceres M., and Patterson T.F. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 12 (1998) 2511-2513
4. Kerdpon D., Pongsiriwet S., Pangsomboon K., Iamaroon A., Kampoo K., Sretrirutchai S., et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral Dis 10 (2004) 138-144
5. Klein R.S., Harris C.A., Small C.B., Moll B., Lesser M., and Friedland G.H. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 311 (1984) 354-358
6. Powderly W.G. Resistant candidiasis. AIDS Res Hum Retroviruses 10 (1994) 925-929
7. Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents [draft]. Accessed June 18, 2009.
8. Revankar S.G., Kirkpatrick W.R., McAtee R.K., Dib O.P., Fothergill A.W., Redding S.W., et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 174 (1996) 821-827
9. Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Rhine-Chalberg J., et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 18 (1994) 240-242
10. Fan-Havard P., Capano D., Smith S.M., Mangia A., and Eng R.H. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 35 (1991) 2302-2305
11. Revankar S.G., Dib O.P., Kirkpatrick W.R., McAtee R.K., Fothergill A.W., Rinaldi M.G., et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 26 (1998) 960-963
12. Martins M.D., Lozano-Chiu M., and Rex J.H. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 27 (1998) 1291-1294
13. Erlandsen JEPP, Vallor AC, Kirkpatrick WR, Thompson GR 3rd, Herrera ML, Wickes BL, et al. Current prevalence of Candida spp. colonization, oropharyngeal candidiasis (OPC) and fluconazole (FLU) resistance in HIV/AIDS patients using combined microbiological and molecular methods of detection. In: Programs and Abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, D.C., 2008. Poster M-718.
14. Westbrook S.D., Kirkpatrick W.R., Freytes C.O., Toro J.J., Bernardo S., Patterson T.F., et al. Candida krusei sepsis secondary to oral colonization in a hemopoietic stem cell transplant recipient. Med Mycol 45 (2007) 187-190
15. Redding S.W., Marr K.A., Kirkpatrick W.R., Coco B.J., and Patterson T.F. Candida glabrata sepsis secondary to oral colonization in bone marrow transplantation. Med Mycol 42 (2004) 479-481
16. Redding S.W., Dahiya M.C., Kirkpatrick W.R., Coco B.J., Patterson T.F., Fothergill A.W., et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97 (2004) 47-52
17. Revankar S.G., Kirkpatrick W.R., McAtee R.K., Dib O.P., Fothergill A.W., Redding S.W., et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med 105 (1998) 7-11
18. Ally R., Schurmann D., Kreisel W., Carosi G., Aguirrebengoa K., Dupont B., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33 (2001) 1447-1454
19. Thompson III G.R., Wiederhold N.P., Vallor A.C., Villareal N.C., Lewis II J.S., and Patterson T.F. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 52 (2008) 3783-3785
20. Laverdiere M., Lalonde R.G., Baril J.G., Sheppard D.C., Park S., and Perlin D.S. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57 (2006) 705-708
21. Fidel Jr. P.L. Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 40 (2002) 359-375
22. Lacasse M., Fortier C., Chakir J., Cote L., and Deslauriers N. Acquired resistance and persistence of Candida albicans following oral candidiasis in the mouse: a model of the carrier state in humans. Oral Microbiol Immunol 8 (1993) 313-318
23. Deslauriers N., Cote L., Montplaisir S., and de Repentigny L. Oral carriage of Candida albicans in murine AIDS. Infect Immun 65 (1997) 661-667
24. de Repentigny L., Aumont F., Ripeau J.S., Fiorillo M., Kay D.G., Hanna Z., et al. Mucosal candidiasis in transgenic mice expressing human immunodeficiency virus type 1. J Infect Dis 185 (2002) 1103-1114
25. Mercante D.E., Leigh J.E., Lilly E.A., McNulty K., and Fidel Jr. P.L. Assessment of the association between HIV viral load and CD4 cell count on the occurrence of oropharyngeal candidiasis in HIV-infected patients. J Acquir Immune Defic Syndr 42 (2006) 578-583
26. Cauda R., Tacconelli E., Tumbarello M., Morace G., De Bernardis F., Torosantucci A., et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 21 (1999) 20-25
27. Fidel Jr. P.L. Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv Dent Res 19 (2006) 80-84
28. Powderly W.G., Mayer K.H., and Perfect J.R. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses 15 (1999) 1405-1412
29. Rabeneck L., and Laine L. Esophageal candidiasis in patients infected with the human immunodeficiency virus. A decision analysis to assess cost-effectiveness of alternative management strategies. Arch Intern Med 154 (1994) 2705-2710
30. Wilcox C.M. Short report: time course of clinical response with fluconazole for Candida oesophagitis in patients with AIDS. Aliment Pharmacol Ther 8 (1994) 347-350
31. Wilcox C.M., Alexander L.N., Clark W.S., and Thompson III S.E. Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology 110 (1996) 1803-1809
32. Pappas P.G., Kauffman C.A., Andes D., Benjamin Jr. D.K., Calandra T.F., Edwards Jr. J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 503-535
33. Hamza O.J., Matee M.I., Bruggemann R.J., Moshi M.J., Simon E.N., Mugusi F., et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis 47 (2008) 1270-1276
34. Phillips P., Zemcov J., Mahmood W., Montaner J.S., Craib K., and Clarke A.M. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 10 (1996) 1369-1376
35. Vazquez J.A., Skiest D.J., Nieto L., Northland R., Sanne I., Gogate J., et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42 (2006) 1179-1186
36. Saag M.S., Fessel W.J., Kaufman C.A., Merrill K.W., Ward D.J., Moskovitz B.L., et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 15 (1999) 1413-1417
37. Fichtenbaum C.J., Zackin R., Rajicic N., Powderly W.G., Wheat L.J., Zingman B.S., and Adult AIDS Clinical Trials Group Study Team 295. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. AIDS 14 (2000) 845-852
38. Skiest D.J., Vazquez J.A., Anstead G.M., Graybill J.R., Reynes J., Ward D., et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 44 (2007) 607-614
39. Hegener P., Troke P.F., Fatkenheuer G., Diehl V., and Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12 (1998) 2227-2228
40. Villanueva A., Arathoon E.G., Gotuzzo E., Berman R.S., DiNubile M.J., and Sable C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33 (2001) 1529-1535
41. de Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39 (2004) 842-849
42. Krause D.S., Simjee A.E., van Rensburg C., Viljoen J., Walsh T.J., Goldstein B.P., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39 (2004) 770-775
43. Dewsnup D.H., and Stevens D.A. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol 32 (1994) 389-393
44. Vazquez J.A., Hidalgo J.A., and De Bono S. Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. HIV Clin Trials 1 (2000) 23-29
45. Bodasing N., Seaton R.A., Shankland G.S., and Pithie A. Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemother 50 (2002) 765-766
46. Goldman M., Cloud G.A., Wade K.D., Reboli A.C., Fichtenbaum C.J., Hafner R., et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 41 (2005) 1473-1480
47. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts (2002) Approved standard neM-ANCfCL
48. Barry A.L., and Brown S.D. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 34 (1996) 2154-2157
49. Pfaller M.A., Boyken L., Messer S.A., Tendolkar S., Hollis R.J., and Diekema D.J. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol 43 (2005) 5208-5213
50. Patterson T.F., Revankar S.G., Kirkpatrick W.R., Dib O., Fothergill A.W., Redding S.W., et al. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol 34 (1996) 1794-1797
51. White T.C., Marr K.A., and Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11 (1998) 382-402
52. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Update 10 (2007) 121-130
53. White T.C., Holleman S., Dy F., Mirels L.F., and Stevens D.A. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46 (2002) 1704-1713
54. Coste A., Turner V., Ischer F., Morschhauser J., Forche A., Selmecki A., et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172 (2006) 2139-2156
55. Coste A., Selmecki A., Forche A., Diogo D., Bougnoux M.E., d'Enfert C., et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryotic cell 6 (2007) 1889-1904
56. Morschhauser J., Barker K.S., Liu T.T., Bla B.W.J., Homayouni R., and Rogers P.D. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 3 (2007) e164
57. Schubert S., Rogers P.D., and Morschhauser J. Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimicrob Agents Chemother 52 (2008) 4274-4280
58. Ferrari S., Ischer F., Calabrese D., Posteraro B., Sanguinetti M., Fadda G., et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog 5 (2009) e1000268
59. Hernandez S., Lopez-Ribot J.L., Najvar L.K., McCarthy D.I., Bocanegra R., and Graybill J.R. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 48 (2004) 1382-1383
60. Douglas C.M., D'Ippolito J.A., Shei G.J., Meinz M., Onishi J., Marrinan J.A., et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 41 (1997) 2471-2479
61. Douglas C.M., Marrinan J.A., Li W., and Kurtz M.B. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol 176 (1994) 5686-5696
62. Kurtz M.B., Abruzzo G., Flattery A., Bartizal K., Marrinan J.A., Li W., et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 64 (1996) 3244-3251
63. Park S., Kelly R., Kahn J.N., Robles J., Hsu M.J., Register E., et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob Agents Chemother 49 8 (2005) 3264-3273